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Dear Editor, 27 
 Familial thrombocytosis (FT) is a rare, inherited form of myeloproliferative 28 
neoplasms (MPN). Germline mutations have been identified mostly in THPO [1] and 29 
MPL [2] genes, while only 6 JAK2 germline mutations in 5 families have been reported 30 
[3-6]. In a previous report, all the members of a family affected with the JAK2 R867Q 31 
mutation showed thrombocytosis alone with normal hemoglobin levels [6]. Here we 32 
 3 
report a Japanese FT pedigree with the germline JAK2 R867Q mutation, in whom 33 
progression to polycythemia vera (PV) was observed. 34 
 A 31-year-old woman (patient 5) with a 25-year history of thrombocytosis 35 
was referred to our hospital (Fig. 1a). Her hemoglobin level was normal. Her father 36 
(patient 3) also showed mild thrombocytosis, but had high hemoglobin levels with 37 
normal to low erythropoietin levels. His platelets had been persistently high and his 38 
hemoglobin levels fluctuated around 16.5 g/dl until he was 56. However, since the age 39 
of 59, his hemoglobin levels have been apparently high (> 18 g/dl) while platelet counts 40 
have been gradually decreasing (Fig. 1b). His hematocrit levels were also high (53.2%), 41 
and mean corpuscular volume was within normal range (95 fl). He had mild 42 
splenomegaly. The differential count of his white blood cells was within normal range 43 
(Band neutrophils: 2.5%; Segmented neutrophils: 54.5%; Lymphocytes: 25.5%; 44 
Monocytes: 4%; Eosinophils: 3%; Basophils: 1%). His erythropoietin level was 45 
3.0-18.4 mIU/ml (normal range, 9.1-32.8). Bone marrow biopsy of patient 3 performed 46 
at the age of 62 showed hypercellularity with panmyelosis and loose network of 47 
reticulin in perivascular areas. (Fig. 1c-d). The cytogenetics of bone marrow was normal 48 
 4 
(46, XY[20]). These results suggest that patient 3 showed ET-like phenotype at first, but 49 
now meets the criteria for PV. Some family members of patients 3 and 5, including a 50 
0-year-old infant, also showed marked thrombocytosis (Fig. 1a), which raised the 51 
possibility of familial MPN. Using targeted DNA sequencing in neutrophils, we 52 
explored 67 genes that are implicated in myeloid malignancies for patients 3 and 5 [7] 53 
and found heterozygous JAK2 R867Q mutations in both cases. We also found a 54 
stop-gain mutation of TET2 S271X with an allele frequency of 5% in patient 3, and no 55 
relevant somatic mutations in patient 5. Next, we performed Sanger sequencing using 56 
neutrophils (from patients 1 to 7) and buccal swabs (from patients 1 to 8) in the present 57 
family members. All affected members (patients 3, 5, 6, and 8) had the heterozygous 58 
JAK2 R867Q mutations in their neutrophils and buccal swabs. In contrast, unaffected 59 
members lacked the JAK2 R867Q mutation.  60 
Our data were mostly consistent with the first report of the pedigree harboring 61 
the JAK2 R867Q mutation. In the report, all 3 affected members were adults at 62 
diagnosis, and showed only thrombocytosis [6]. Observations of our pedigree further 63 
demonstrated that thrombocytosis could be seen soon after birth and that transformation 64 
 5 
to PV could occur. According to the previous report, R867Q is a gain-of-function 65 
mutation that activates thrombopoietin signaling depending on the presence of the 66 
thrombopoietin receptor, but does not affect erythropoietin signaling [6]. Thus, we 67 
hypothesized that transformation to PV in patient 3 might be caused by additional 68 
somatic mutations; however, we did not find any relevant additional somatic mutations. 69 
Considering the low allele frequency, the TET2 mutation found in patient 3 may not be 70 
related to transformation to PV, but might be consistent with age-related clonal 71 
hematopoiesis. Future genome-wide studies may unveil the mechanism of the 72 
phenotypic switch from thrombocytosis to PV in germline JAK2 R867Q-related FT. 73 
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 Figure legends 129 
Fig. 1 a Pedigree with familial thrombocytosis. Filled black symbols represent members 130 
with thrombocytosis. Informed consent was obtained from 8 out of 10 living family 131 
members (patient 1-8). Wt, wild type. Het, heterozygous. b Clinical course of patient 3. 132 
c Hematoxylin-eosin staining of bone marrow in patient 3. x200 magnification. d Silver 133 
staining of bone marrow in patient 3. x200 magnification. 134 
